A new publication referencing plecanatide was released on September 1, 2026. The paper, titled "Patients' Real-World Experiences With Pharmacologic Therapies for Irritable Bowel Syndrome With Constipation: A Mixed-Methods Analysis and Classification of Social Media and E-Forum Posts," appeared in Neurogastroenterology and Motility.
The publication is described as a mixed-methods analysis and classification of posts drawn from social media and e-forums. It focuses on patient experiences with pharmacologic therapies used for irritable bowel syndrome with constipation, a condition for which plecanatide is an approved treatment.
No findings, outcomes, or conclusions from the study have been provided alongside this announcement. This brief reports only the existence and bibliographic details of the publication, not its content or results.
Readers interested in the specific data, methodology, or conclusions of this analysis should consult the full text through the journal or the PubMed listing. As with any new publication, its findings should be reviewed in the context of the broader body of research on IBS-C treatments.
For more background on plecanatide, including its approved status and general information, readers can consult the compound overview.